PRP, the P-Shot and Stem-Cell Treatments for Erectile Dysfunction: Established or Experimental?

The short version

• The AUA guideline states that for men with ED, platelet-rich plasma therapy should be considered experimental. That statement rests on Expert Opinion — the lowest evidence tier the guideline uses.
• The same guideline states that intracavernosal stem cell therapy should be considered investigational (Conditional Recommendation, Evidence Level Grade C).
• “Experimental” sits below “investigational.” Neither term means proven. Both mean the treatment’s proper setting is research.
• Branded procedure names are marketing, not regulatory status. A trademarked name for a PRP injection protocol tells you nothing about evidence, approval or standardisation.
• There is no standardised PRP product. Preparation method, platelet concentration, leucocyte content and injection technique vary between clinics, so two men receiving “PRP” may receive substantially different things.
• The FDA has warned repeatedly about unapproved regenerative and stem-cell products marketed directly to patients for conditions they are not approved to treat.
• These are cash-pay treatments, often sold in packages, and are not covered by insurance.

What these treatments are

Platelet-rich plasma

PRP is prepared from your own blood. A sample is drawn and centrifuged to concentrate the platelets, and that concentrate is injected into the target tissue. Platelets carry growth factors, and the hypothesis is that concentrating them at a site of injury or degeneration recruits a repair response.

The reasoning is the same across every field where PRP is marketed — orthopaedics, hair loss, facial aesthetics, sexual medicine. It is biologically plausible. Plausibility is not evidence, and PRP has now been plausible for well over a decade in several fields without becoming established in most of them.

One consequence of PRP being autologous — made from your own blood — is that it occupies a lighter regulatory category than a manufactured drug. That is a statement about regulatory pathway, not about efficacy, and it is frequently presented to patients as though it were a safety endorsement.

Stem-cell preparations

Intracavernosal stem cell therapy involves injecting cell preparations, typically derived from adipose tissue or bone marrow, into the erectile tissue. The hypothesis is regeneration of vascular and smooth muscle tissue. The AUA classifies it as investigational.

Products marketed as “stem cell” treatments in commercial clinics vary enormously and frequently contain few or no viable stem cells. The FDA has taken repeated action against clinics marketing unapproved regenerative products, and has warned consumers directly about stem-cell products promoted for conditions they are not approved to treat.

What the evidence tier actually means

Guideline language is precise, and the precision is the useful part.

• Experimental (PRP, Expert Opinion). The panel could not identify a body of evidence adequate even to grade. The recommendation reflects the considered view of the panel rather than accumulated trial data.
• Investigational (stem cell therapy; also shockwave therapy, Grade C). Some evidence exists, but it is insufficient in quality or quantity to establish the treatment as standard care.
• Neither term is a synonym for “new but working.” Treatments have sat in these categories for years and then failed adequately powered trials.

Small studies of PRP for erectile dysfunction have reported improvements in questionnaire scores, and further trials continue. Encouraging small studies are how most treatments begin, including the many that do not survive larger ones. The honest position is that this is interesting and unproven.

Specific things to be cautious about

• Branded procedure names. A trademarked name describes a protocol somebody has packaged, not a regulatory status or an evidence base.
• Combination selling. These treatments are frequently bundled with shockwave therapy, testosterone, supplements or devices in a single expensive package. Bundling makes it impossible to attribute any improvement to any component, and it raises the price.
• Testimonial-led marketing. Erectile function endpoints are self-reported and placebo-responsive. Testimonials are the weakest possible evidence for exactly this kind of outcome.
• “FDA-registered” and “FDA-cleared” language. Facility registration is not product approval, and clearance of a centrifuge or a kit is not approval of a treatment for erectile dysfunction.
• Anything offering stem cells for erectile dysfunction outside a registered clinical trial. If you want to participate in research, ask directly whether there is a registered trial you could enrol in.

Risks of the procedures themselves are generally described as modest — injection-site pain, bruising, swelling, and infection risk inherent to any injection. The larger risk for most people is financial, and the opportunity cost of not pursuing an evaluation that would have found a treatable vascular or metabolic cause.

Why “it is your own blood” is not a safety argument

The most persuasive line used to sell platelet-rich plasma is that it is autologous — made from you. It is worth unpacking, because it conflates three separate things.

First, autologous does mean the risk of immune reaction or transmitted infection from a donor is essentially removed. That is real and it is why the procedure’s safety profile is generally described as favourable.

Second, autologous status is the reason these preparations sit in a lighter regulatory category than a manufactured drug. That is a statement about which regulatory pathway applies, not a finding that the treatment works. It is routinely presented to patients as though a lighter pathway were an endorsement, when it is closer to the opposite: less scrutiny, not more.

Third, and most importantly, safety and efficacy are independent questions. A treatment can be very unlikely to hurt you and still not help you. The AUA classification of platelet-rich plasma as experimental is a statement about efficacy evidence. It is entirely compatible with the procedure being low-risk.

The residual risks are those of any injection: pain, bruising, swelling, and a small infection risk. For most people the dominant risk is financial, plus the opportunity cost of an untreated vascular or metabolic cause.

The standardisation problem

There is no single thing called platelet-rich plasma. Preparations differ in ways that plausibly matter and that no clinic is obliged to disclose.

• Platelet concentration varies several-fold between preparation systems. Studies rarely report it in a way that allows comparison.
• Leucocyte content differs between leucocyte-rich and leucocyte-poor preparations, and there is active debate about which is preferable in which tissue.
• Centrifugation protocol — speed, duration, number of spins — changes the product.
• Activation method, whether the platelets are activated before injection and how, is inconsistent across studies.
• Injection technique, including site, depth, volume and number of sessions, is not standardised.

The practical consequence is that two men who each received “PRP for erectile dysfunction” may have received substantially different biological products by substantially different techniques. This is a large part of why the evidence base has not converged, and it is why a positive small study does not straightforwardly transfer to the clinic down the road.

If you are considering it, ask what preparation system is used and what platelet concentration it produces. The answer, or the absence of one, is informative.

If you want access to these treatments legitimately

There is a route that is both cheaper and more useful than paying a clinic: enrol in a registered trial.

Registered trials of platelet-rich plasma and of cell-based therapy for erectile dysfunction are listed publicly. Participation usually means the intervention is provided at no cost, that you are assessed properly at baseline and follow-up, and that your outcome is recorded and contributes to answering the question. Paying a commercial clinic outside a trial does none of those things: your result is not recorded anywhere, it helps no future patient, and it does not move the field.

Ask any clinician offering these treatments whether there is a trial you could enrol in instead. A clinician genuinely interested in whether the treatment works will know the answer. One who reacts badly to the question has told you something about their interest.

What the procedures involve

Platelet-rich plasma

A blood sample is drawn, usually from the arm, and spun in a centrifuge to separate and concentrate the platelet fraction. That concentrate is then injected into the erectile tissue, typically at several sites along the shaft, usually after topical or local anaesthesia. The whole appointment is short. Most men report injection-site discomfort, bruising or mild swelling for a few days.

Courses are commonly sold as two to three sessions spaced weeks apart, with maintenance sessions suggested afterwards. The suggestion of maintenance is worth noticing: it converts a one-off purchase into a recurring one before any benefit has been established.

Cell-based preparations

Preparations described as stem-cell therapy are usually derived from adipose tissue, obtained by a small liposuction procedure, or from bone marrow. The material is processed and injected into the erectile tissue. This is a more involved procedure with a harvest step, and it carries the risks of that step as well as of the injection.

A significant caution applies here that does not apply to platelet-rich plasma. Products marketed commercially as stem-cell treatments vary enormously in what they actually contain, and many contain few or no viable stem cells. The FDA has taken repeated enforcement action against clinics marketing unapproved regenerative products and has issued direct consumer warnings about stem-cell and exosome products promoted for conditions they are not approved to treat.

What the evidence tiers mean in practice

Guideline language is precise, and the precision carries information a patient can use.

• Experimental, applied to platelet-rich plasma on the basis of Expert Opinion, is the weakest designation the guideline issues. It signals that the panel could not identify a body of evidence adequate even to grade formally, so the statement rests on the considered judgement of the panel rather than on pooled trial data.
• Investigational, applied to intracavernosal stem cell therapy as a Conditional Recommendation at Evidence Level Grade C, signals that some evidence exists but is insufficient in quality or volume to establish the treatment as standard care. The same designation and grade apply to low-intensity shockwave therapy.
• Neither designation means disproven, and neither means unsafe. Both mean the proper setting for the treatment is research.

The distinction between those two tiers is worth holding onto when a clinic bundles them. Platelet-rich plasma and stem-cell preparations are frequently sold together, or alongside shockwave therapy, as a single regenerative package. They do not sit at the same evidence tier, they are not the same kind of intervention, and combining them makes it impossible to attribute any improvement to any component while reliably increasing the price.

It is also worth knowing that treatments have occupied these categories for years and then failed adequately powered trials. Small studies of platelet-rich plasma for erectile dysfunction have reported improvements in questionnaire scores, and further trials continue. Encouraging small studies are how most treatments begin, including the many that do not survive larger ones. The honest position today is that this is interesting, low-risk, and unproven.

Why this pattern recurs across every field

Platelet-rich plasma is marketed for hair loss, facial rejuvenation, joint pain, tendon injury and sexual function. The pitch is nearly identical in each: your own blood, growth factors, natural healing, regenerative.

The underlying biology is genuinely plausible, which is why the idea has persisted for well over a decade. But plausibility has a poor track record as a predictor. Many biologically sensible interventions have failed adequately powered, sham-controlled trials, and in most fields where platelet-rich plasma has been marketed it has not become established practice.

The pattern to watch for is a treatment that arrives in the clinic already priced, branded and bundled before the evidence exists to place it. That sequence — commercialisation ahead of evidence — is the recurring feature, and it is why guideline panels reach for words like experimental. It is not scepticism about regeneration as an idea. It is scepticism about buying before the answer is known.

What to do first instead

If you have arrived at this page because you are considering paying for a regenerative treatment, there is a cheaper sequence that is better supported at every step.

Start with the evaluation. Erectile dysfunction is frequently the first symptom of a vascular or metabolic problem, and the assessment that finds it — blood pressure, lipids, glucose or HbA1c, medication review, and a proper history — is ordinary medical care, usually covered, and costs a fraction of a single injection session. A meaningful number of men discover at that visit that the cause is a medication they are taking, or an untreated condition, and the answer is a substitution rather than a procedure.

Then trial established treatment properly. Apparent failure of PDE5 inhibitors is often an inadequate dose, too few attempts, or an expectation that the tablet works without sexual stimulation. A treatment has not failed until it has been tried correctly, and the regenerative market is substantially populated by men who believe they are non-responders when they are not.

If established treatment genuinely does not suit you, the other options with real evidence — vacuum devices, intraurethral or intracavernosal therapy, and implant surgery in appropriately selected men — sit above platelet-rich plasma and cell therapy on the evidence ladder, not below them. Implant surgery in particular has high reported satisfaction in men who have exhausted less invasive options, and is often mentioned far later in the conversation than it should be.

That sequence is not a way of telling you no. It is the order that gives you the best chance of a result, and it leaves the experimental option available afterwards if you still want it — by which point you will know your cause, your severity, and your response to everything established, which is exactly the information that makes an experimental choice an informed one rather than a hopeful one.

What it costs, and what insurance usually will not cover

We publish cost bands rather than prices. Prices vary by region, practice and contract, and a specific figure printed on a web page is wrong within months. Ask any practice for a written quotation before agreeing to treatment.

Typical band. Sold per session and commonly in multi-session packages, in a high band for a full course. Combination packages that add shockwave therapy or hormone treatment sit higher still.

What the band usually excludes. The package price typically excludes the initial evaluation, laboratory work, PDE5 inhibitors used alongside, any repeat course, and treatment of the underlying cardiovascular or metabolic condition if one is found.

Coverage. Not covered. Because the AUA classifies PRP as experimental and stem cell therapy as investigational, and neither is FDA-approved for erectile dysfunction, these are cash-pay treatments. The evaluation of erectile dysfunction itself is ordinary medical care and is usually covered — that part is worth doing first regardless of what you decide about the injections.

On cheaper routes. Treatment obtained abroad, devices bought online for home use, and procedures performed by unlicensed providers are all cheaper. We describe that these routes exist and why we do not guide readers to them. We do not publish sourcing instructions for them.

In development

Nothing in this section is available to you now. It is here so you can recognise the names when you meet them, not so you can seek them out.

Randomised and sham-controlled trials of platelet-rich plasma for erectile dysfunction are ongoing, as is work on cell-based therapies. Investigators have generally called for larger trials before any conclusion is drawn. Enrolment in a registered clinical trial is a legitimate way to access these treatments; paying a clinic outside a trial is not the same thing and generates no usable evidence for anyone.

Sources

1. American Urological Association. Erectile Dysfunction: AUA Guideline. Statement 23 (low-intensity extracorporeal shock wave therapy: investigational; Conditional Recommendation, Evidence Level Grade C); Statement 24 (intracavernosal stem cell therapy: investigational); Statement 25 (platelet-rich plasma therapy: experimental, Expert Opinion).
2. FDA. Consumer alert on regenerative medicine products including stem cells and exosomes.
3. FDA. Regenerative medicine advanced therapy designation and enforcement of unapproved products.
4. ClinicalTrials.gov — registered trials of platelet-rich plasma and cell therapy for erectile dysfunction.

Related reading

• Erectile dysfunction: why it can be an early sign of cardiovascular disease
• Shockwave therapy for erectile dysfunction
• Avoiding health misinformation